Medifast (NYSE:MED) Releases Q1 2025 Earnings Guidance

Medifast (NYSE:MED) issued an update on its first quarter 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of -0.500-0.000 for the period, compared to the consensus EPS estimate of -0.190. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.8 million.

Wall Street Analysts Forecast Growth

Separately, DA Davidson dropped their price objective on Medifast from $17.00 to $16.50 and set a “neutral” rating for the company in a research note on Wednesday.

Medifast Price Performance

MED stock opened at $14.35 on Thursday. Medifast has a 12-month low of $14.16 and a 12-month high of $49.90. The stock has a market capitalization of $156.96 million, a price-to-earnings ratio of 79.71 and a beta of 1.14. The company has a current ratio of 3.11, a quick ratio of 2.55 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average price is $16.49 and its two-hundred day moving average price is $18.02.

Medifast (NYSE:MED) last issued its quarterly earnings data on Tuesday, February 18th. The specialty retailer reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.26. The firm had revenue of $119.00 million for the quarter, compared to analyst estimates of $114.25 million. Medifast had a return on equity of 10.66% and a net margin of 0.35%. As a group, equities analysts predict that Medifast will post 0.51 earnings per share for the current year.

About Medifast

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.